nach oben

Erschienen in:

07.11.2019 | Case Report

A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control

verfasst von: Kazutaka Iijima, Mitsuharu Oozeki, Kaori Ikeda, Hiroyuki Honda, Hajime Ishibashi, Masaharu Yamaoka, Shinji Fujieda, Hitoaki Saitoh, Mitsuhide Goto, Masahiro Araki, Kenji Amagai

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Small bowel adenocarcinomas are rare. There is no definite consensus as to whether they should be treated in a manner similar to gastric or to colon cancer. We report the case of a young woman with a primary jejunal adenocarcinoma, bilateral ovary metastases, and peritoneal dissemination. First- and second-line chemotherapy for the gastric cancer failed. She was then treated with the immune checkpoint inhibitor nivolumab and had temporary improvement in her condition. To the best of our knowledge, this is the first case wherein nivolumab has been used to treat small bowel adenocarcinoma.

Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev. 1998;7:243–51.

Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973–1990. Int J Epidemiol. 1996;25:722–8.CrossRef

Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.CrossRef

Shenoy S. Genetic risks and familial associations of small bowel carcinoma. World J Gastrointest Oncol. 2016;8:509–19.CrossRef

Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46:97–104.CrossRef

Syngal S, Brand RE, Church JM, American College of Gastroenterology, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.CrossRef

Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology. 2000;119(06):1447–53.CrossRef

Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731–43.CrossRef

Aparicio T, Zaanan A, Mary F, et al. Small bowel adenocarcinoma. Gastroenterol Clin North Am. 2016;45:447–57.CrossRef

10.

Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila). 2011;4:1–5.CrossRef

11.

Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9.CrossRef

12.

Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 2006;101:2826–32.CrossRef

13.

Hong SH, Koh YH, Rho SY, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39:54–61.CrossRef

14.

Takayoshi K, Kusaba H, Uenomachi M, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80:333–42.CrossRef

15.

Howe JR, Karnell LH, Menck HR, et al. Adenocarcinoma of the small bowel: review of the National Cancer Data Base. Cancer 1985-1995;86:2693–2706.

16.

Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199:797–803.CrossRef

17.

Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518–26.CrossRef

18.

Umman P, Adiyodi V, Narayan C. Small bowel adenocarcinoma—report of two cases and review of literature. Indian J Surg. 2013;75:123–7.CrossRef

19.

Hong SH, Koh YH, Rho SY, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39:54–61.CrossRef

20.

Schwameis K, Schoppmann SF, Stift J, et al. Small bowel adenocarcinoma—terra incognita: a demand for cross-national pooling of data. Oncol Lett. 2014;7:1613–7.CrossRef

21.

Lech G, Korcz W, Kowalczyk E, et al. Primary small bowel adenocarcinoma: current view on clinical features, prognostic factors, treatment and outcome. Scand J Gastroenterol. 2017;52:1194–202.CrossRef

22.

Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27:2598–603.CrossRef

23.

Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23:561–6.CrossRef

24.

Clinical Practice Guidelines in Oncology Colon cancer version 1.2019-March 15,2019. (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed 2019 March 28.

25.

Kotoe T, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80:333–42.CrossRef

26.

Gulhati P, Raghav K, Shroff R, et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist. 2018;23:277e26.CrossRef

27.

Otsuji E, Yamaguchi T, Sawai K, et al. Characterization of signet ring cell carcinoma of the stomach. J Surg Oncol. 1998;67:216–20.CrossRef

28.

Makino T, Mishima H, Ikenaga M, et al. Clinicopathologic features of signet-ring cell carcinoma of the colon and rectum. Jpn J Gastroenterol Surg. 2006;39:16–22.CrossRef

29.

Liu An-Chieh, Chen Ch, et al. A rare Krukenberg tumor arising from a primary adenocarcinoma of the small intestine. Taiwan J Obstet Gynecol. 2018;57(2):319–22.CrossRef

30.

Woodruff JD, Novak ER. The Krukenberg tumor: study of 48 cases from the ovarian tumor registry. Obstet Gynecol. 1960;15:351–60.

31.

Mitsushita J, Tanaka A, et al. Metastatic ovarian tumors originating from a small bowel adenocarcinoma–a case report and brief literature review. Int J Gynecol Pathol. 2017;36(3):253–60.CrossRef

32.

Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.CrossRef

33.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5).

34.

Shahabi V, Postow MA, et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 2015;38(1):90–7.CrossRef

35.

Seyedin SN, Schoenhals JE, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7(9):967–80.CrossRef

36.

Hecht MI, Büttner-Herold M, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.CrossRef

37.

De Wolf K, Kruse V, et al. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med. 2017;31;15(1):21.

38.

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.CrossRef

39.

Kim ST, Cristescu R, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.CrossRef

Titel: A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control
verfasst von: Kazutaka Iijima
Mitsuharu Oozeki
Kaori Ikeda
Hiroyuki Honda
Hajime Ishibashi
Masaharu Yamaoka
Shinji Fujieda
Hitoaki Saitoh
Mitsuhide Goto
Masahiro Araki
Kenji Amagai
Publikationsdatum: 07.11.2019
Verlag: Springer Singapore
Erschienen in: Clinical Journal of Gastroenterology / Ausgabe 3/2020
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-019-01064-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report

Ectopic pancreatitis in the antral stomach causing gastric outlet obstruction: a case of successful resection

A rare case of peliosis hepatis in a patient with chronic renal failure and renal cell carcinoma

A case of gastric pseudoaneurysm following endoscopic submucosal dissection of early gastric cancer

An autopsy case of granulocyte colony-stimulating factor-producing pancreatic adenosquamous carcinoma

Acute pancreatitis induced by Tadalafil: a case report